The Big Cure for 2013 - Research Report on Biogen Idec Inc. and Keryx Biopharmaceuticals Inc.

    The Big Cure for 2013 - Research Report on Biogen Idec Inc. and Keryx
                           Biopharmaceuticals Inc.

Investors and patients are almost free from malaise after Biogen and Keryx
announced good news that improved the outlook for the biopharmaceutical
industry this year

PR Newswire

NEW YORK, January 23, 2013

NEW YORK, January 23, 2013 /PRNewswire/ --

Biogen Idec Inc. (NASDAQ:BIIB) [Full Research Report]^[1] and Keryx
Biopharmaceuticals Inc. (NASDAQ:KERX) [Free Research Report]^[^2^] both
announced that marketing approvals are underway for their respective
treatments, recombinant factor IX Fc fusion protein (rFIXFC) and Zerenex.
Biogen's rFIXFC is the first product candidate in a new class of long-lasting
clotting factor therapy for the treatment of hemophilia B. Keryx' Zerenex
(ferric citrate) is an oral, iron-based compound for the treatment of kidney
disease.

After separate disappointing news from Biogen and Keryx regarding the failure
of their previous drug treatments for ALS and colorectal cancer, their good
news this year are expected to push their sales and trading volumes to
record-highs. Analysts are bullish that both companies can rake in significant
revenues to brighten the shine of the lackluster biopharmaceutical industry.
The probability of success is still not solid for Biogen or Keryx, but the
positive outlook towards sales forecasts and stock advances for each company
remains strong. Until the FDA green lights the marketing of both drugs can
everyone be certain of a new reason to celebrate.

The huge factor which clouds the issue of size is the bull inflection which
analysts and investors stood by during the toughest of times. Despite the huge
risk when it comes to research and development, neither Biogen nor Keryx is at
risk of suffering a tragic downfall. For instance, the risk of Keryx in going
bankrupt is surprisingly close to none compared to its risk of getting
disappointing results from phase 3 trials. It seems too hard to believe, but
the development stage company actually gets royalty payments from its Japanese
partner, JT Torii, every time it climbs a notch up the ladder. This is a good
way for the company to cope with its run rate.

The success of Biogen and Keryx are yet to be solidified, but the signs are
looking good. Most US investors tend to overlook the biopharmaceutical
industry, and now is the right time to get their attention. Investing on
companies like Biogen and Keryx during this time is may be foolproof. Biogen
is one of the industry's best performers while Keryx is on the rise to compete
with big names without too much risk through creating profitable partnerships.

Reference Links:

^[1]The Full Research Report on Biogen Idec Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/37fb_BIIB]

^[^2^]The Free Research Report on Keryx Biopharmaceuticals Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/7972_KERX]

Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop -- long before they become
the next top news on major financial networks.

Contact: Demi Lapierre
Email: press@NationalTradersAssociation.org
Main: +1-(702)-212-4493

SOURCE National Traders Association
 
Press spacebar to pause and continue. Press esc to stop.